Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022

-$0.0283 (-8.37%) Today
+$0.01 (+3.23%) As of 8:37 PM UTC after-hours

Why Robinhood?

You can watch OTLKW and buy or sell other stocks, options, and ETFs commission-free!

About OTLKW

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

CEO
Lawrence A. Kenyon, CPA
Employees
—
Headquarters
Iselin, New Jersey
Founded
2010

OTLKW Key Statistics

Market Cap
—
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
21.86K
High Today
$0.3895
Low Today
$0.3003
Open Price
$0.3895
Volume
27.72K
52 Week High
$3.49
52 Week Low
$0.09
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure